Published in Medical Letter on the CDC and FDA, September 5th, 2004
This phase 1 trial will be a single-dose, dose-escalation study to establish the safety, pharmacokinetic, and pharmacodynamic profile of TRX4. Approximately thirty moderate to severe psoriasis subjects will be enrolled. The clinical trial is being conducted pursuant to an investigational new drug (IND) application filed with the U.S. Food and Drug Administration.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.